Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.

A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.

47% of Americans believe they will not be able to afford health insurance coverage, care, and pharmaceuticals this year.

Novartis CEO Vas Narasimhan received $32.4 million in total realized compensation in 2025, a marked increase compared to his take home pay in 2024. Narasimhan received 24.9 million Swiss Francs last ...

This week in Other Barks & Bites: a major apparel industry organization releases a study showing that nearly half of ...

Novartis forecast its first annual drop in operating profit in a decade on Wednesday, even as it indicated that long ‌term, the company could ‌potentially offset the patent expiry of ...

ANALYSIS. The pharma giant is under pressure as its two largest patents expire within the next 3 years amid a challenging US market. Its competitor is expected to benefit from a respite.

So, we see the opportunity to continue to growth dynamically in HS. We think we have an outstanding data profile even versus the incoming competitors. And we also see an opportunity for a market ...

Novartis AG (NYSE:NVS) Q4 2025 Earnings Call Transcript February 4, 2026 Novartis AG beats earnings expectations. Reported ...

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...

Novartis AG (NVS) reports robust full-year financial performance with significant growth in key products, despite facing challenges in Q4 and upcoming patent expirations.

Novartis’ fourth-quarter performance saw net sales decline 1% at constant currencies to $13.3 billion, a reflection of the accelerating impact of U.S. competition and revenue deduction adjustments, ...